Transcept Pharmaceuticals, Inc.
1003 W. Cutting Boulevard
Suite 110
Pt. Richmond
California
94804
United States
Tel: 510-215-3500
Fax: 510-215-3535
Website: http://www.transcept-pharma.com/
Email: info@transcept-pharma.com
155 articles about Transcept Pharmaceuticals, Inc.
-
Paratek Pharmaceuticals, Inc. Completes Merger With Transcept Pharmaceuticals, Inc.
10/31/2014
-
Transcept Pharmaceuticals, Inc. Announces Results Of Special Meeting
10/29/2014
-
Transcept Pharmaceuticals, Inc. Declares Special Dividend Of $12.79 Million And Additional Contingent Future Amounts In Connection With Its Merger With Paratek Pharmaceuticals, Inc.
10/15/2014
-
Bay Area's Transcept Pharmaceuticals, Inc. Soars On Plans To Merge With Paratek Pharmaceuticals, Inc., Picks Up $93 Million Along The Way; Transcept Stock Up +19.60% At Market Close (July 1, 2014)
7/1/2014
-
Transcept Pharmaceuticals, Inc. Declares Special Cash Dividend Of $25 Million
5/14/2014
-
Transcept Pharmaceuticals, Inc. Reports First Quarter 2014 Financial Results
5/6/2014
-
Transcept Pharmaceuticals, Inc. Final Voting Results For Special Meeting Of Stockholders Provide Strong Support For Current Board Of Directors And Tax Benefit Preservation Program
12/20/2013
-
Transcept Pharmaceuticals, Inc. Statement On The Withdrawal Of The Unsolicited Indication Of Interest From Retrophin, LLC
12/18/2013
-
Transcept Pharmaceuticals, Inc. Announces That Largest Stockholder, Roumell Asset Management, Declares Support Of Company Strategies
12/17/2013
-
Transcept Pharmaceuticals, Inc. Announces That Glass Lewis Recommends "AGAINST" All Proposals Subject To A Vote At The December 19, 2013 Special Meeting Of Stockholders
12/16/2013
-
Retrophin, LLC Withdraws Offer For Transcept Pharmaceuticals, Inc.
12/16/2013
-
Transcept Pharmaceuticals, Inc. Announces That ISS Proxy Advisory Services Recommends "AGAINST" All Proposals Subject To A Vote At The December 19, 2013 Special Meeting Of Stockholders
12/12/2013
-
Beaten-Down Transcept Pharmaceuticals, Inc. To Liquidate If It Does Not Find A Buyer By Q1
12/5/2013
-
Transcept Pharmaceuticals, Inc. To Eliminate 43 Percent Of Workforce; Shakes-Up Board
11/14/2013
-
Transcept Pharmaceuticals, Inc. Reports Third Quarter Financial Results
11/8/2013
-
Transcept Pharmaceuticals, Inc. to Report Third Quarter 2013 Financial Results and Host Conference Call on November 7, 2013
11/5/2013
-
Transcept Pharmaceuticals, Inc. Sets Special Stockholders Meeting
10/7/2013
-
Transcept Pharmaceuticals, Inc. Statement on Request by Retrophin, LLC to Acquire Up To 15 Percent of the Outstanding Common Stock of Transcept
9/30/2013
-
Transcept Pharmaceuticals, Inc. Licenses Migraine Drug, But Rejects Martin Shkreli's Takeover Offer
9/26/2013
-
Transcept Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories Announce Global Licensing Agreement for Advanced Acute Migraine Treatment
9/26/2013